Suzanne Ostrander, Head of Clinical Operations at Prothena, answers questions about Prothena’s new partnership with Walgreens
Q: Why is Prothena partnering with Walgreens? A: Our collaboration with Walgreens should accelerate patient identification and increase access and recruitment for Prothena’s ongoing ASCENT-2 multiple ascending dose clinical trial, which is evaluating the safety and tolerability of PRX012. PRX012 is a potential best-in-class anti-Aβ antibody under development for the treatment of Alzheimer’s disease […]